Structure Therapeutics Inc. (NASDAQ:GPCR) Given Average Recommendation of “Buy” by Brokerages

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) have earned an average rating of “Buy” from the eight research firms that are presently covering the firm, Marketbeat.com reports. Eight investment analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have covered the stock in the last year is $81.29.

A number of equities analysts have recently commented on GPCR shares. Stifel Nicolaus started coverage on shares of Structure Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $50.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $80.00 target price on shares of Structure Therapeutics in a research report on Thursday, December 19th. Morgan Stanley started coverage on shares of Structure Therapeutics in a research report on Monday, September 23rd. They set an “overweight” rating and a $118.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 target price on shares of Structure Therapeutics in a research report on Monday, September 23rd. Finally, JMP Securities reissued a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a report on Wednesday, December 18th.

Hedge Funds Weigh In On Structure Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP grew its holdings in Structure Therapeutics by 2.9% in the third quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company’s stock worth $341,015,000 after purchasing an additional 221,851 shares during the last quarter. FMR LLC lifted its stake in shares of Structure Therapeutics by 6.7% during the third quarter. FMR LLC now owns 6,128,444 shares of the company’s stock worth $268,977,000 after buying an additional 383,635 shares during the period. Janus Henderson Group PLC lifted its stake in shares of Structure Therapeutics by 18.0% during the third quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock worth $173,623,000 after buying an additional 602,609 shares during the period. Driehaus Capital Management LLC lifted its stake in shares of Structure Therapeutics by 3.5% during the second quarter. Driehaus Capital Management LLC now owns 2,577,136 shares of the company’s stock worth $101,204,000 after buying an additional 86,833 shares during the period. Finally, Federated Hermes Inc. lifted its stake in shares of Structure Therapeutics by 6.6% during the second quarter. Federated Hermes Inc. now owns 2,407,206 shares of the company’s stock worth $94,531,000 after buying an additional 150,000 shares during the period. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Stock Performance

Shares of NASDAQ:GPCR opened at $26.89 on Thursday. The firm has a market cap of $1.54 billion, a PE ratio of -36.34 and a beta of -2.78. The firm’s 50 day simple moving average is $31.46 and its 200-day simple moving average is $36.27. Structure Therapeutics has a one year low of $23.50 and a one year high of $62.74.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.